Prelude Therapeutics Inc (NASDAQ: PRLD) on Friday, soared 17.29% from the previous trading day, before settling in for the closing price of $0.68. Within the past 52 weeks, PRLD’s price has moved between $0.63 and $6.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 13.10%. With a float of $35.38 million, this company’s outstanding shares have now reached $42.30 million.
The extent of productivity of a business whose workforce counts for 131 workers is very important to gauge. In terms of profitability, gross margin is 87.46%, operating margin of -1995.91%, and the pretax margin is -1816.76%.
Prelude Therapeutics Inc (PRLD) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Prelude Therapeutics Inc is 47.97%, while institutional ownership is 31.35%. The most recent insider transaction that took place on Mar 25 ’25, was worth 69,250. In this transaction Chief Chemistry Officer of this company bought 100,000 shares at a rate of $0.69, taking the stock ownership to the 480,123 shares. Before that another transaction happened on Mar 25 ’25, when Company’s CEO bought 675,000 for $0.69, making the entire transaction worth $467,438. This insider now owns 1,999,296 shares in total.
Prelude Therapeutics Inc (PRLD) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.19% during the next five years compared to -21.61% drop over the previous five years of trading.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Prelude Therapeutics Inc (PRLD) is currently performing well based on its current performance indicators. A quick ratio of 5.30 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.82, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.05 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
The latest stats from [Prelude Therapeutics Inc, PRLD] show that its last 5-days average volume of 0.39 million was superior to 0.23 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 38.96%. Additionally, its Average True Range was 0.08.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 17.68%, which indicates a significant decrease from 73.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.37% in the past 14 days, which was lower than the 111.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8946, while its 200-day Moving Average is $2.4329. Now, the first resistance to watch is $0.8465. This is followed by the second major resistance level at $0.8932. The third major resistance level sits at $0.9465. If the price goes on to break the first support level at $0.7465, it is likely to go to the next support level at $0.6932. Assuming the price breaks the second support level, the third support level stands at $0.6465.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
Market capitalization of the company is 54.38 million based on 55,155K outstanding shares. Right now, sales total 7,000 K and income totals -127,170 K. The company made 4,000 K in profit during its latest quarter, and -28,730 K in sales during its previous quarter.
